Treatment Strategy for Post-hepatectomy Recurrent Hepatocellular Carcinoma Within the Milan Criteria: Repeat Resection, Local Ablative Therapy or Transarterial Chemoembolization?

The results of treatment for early stage recurrent hepatocellular carcinoma (HCC) remain controversial. This study aimed to analyze the clinical outcomes of recurrent HCC within the Milan criteria following different treatment modalities except liver transplantation. From January 2006 to December 20...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of surgery 2022-08, Vol.84 (Suppl 2), p.384-389
Main Authors: Li, Jing, Yang, Xiaoliang, Huang, Liang, Zhu, Xingwu, Qiu, Maixuan, Yan, Jianjun, Yan, Yiqun, Wei, Shaohua
Format: Article
Language:English
Subjects:
Cardiac Surgery
Care and treatment
Chemoembolization
Clinical outcomes
Hepatectomy
Hepatoma
Homeopathy
Liver
Liver cancer
Materia medica and therapeutics
Medical prognosis
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Neurosurgery
Original Article
Pediatric Surgery
Plastic Surgery
Prognosis
Surgery
Therapeutics
Thoracic Surgery
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The results of treatment for early stage recurrent hepatocellular carcinoma (HCC) remain controversial. This study aimed to analyze the clinical outcomes of recurrent HCC within the Milan criteria following different treatment modalities except liver transplantation. From January 2006 to December 2016, 272 consecutive HCC patients who developed intrahepatic recurrence after hepatectomy that satisfied the Milan criteria and Child–Pugh class A or B liver function were retrospectively enrolled. The outcomes of repeat resection (RR), local ablative therapy (LAT), or transarterial chemoembolization (TACE) were reported, and the prognostic factors of survival were investigated. Among the 272 patients, 136 (50.0%), 71 (26.1%), and 65 (23.9%) received TACE, LAT, and RR treatments, respectively. Treatment-related complications were 9.5%, 11.3%, and 10.7%, respectively, in the three groups. No patient died of treatment-related complication. The 1-, 3-, and 5-year overall survival rates after recurrence were 95.0%, 54.2%, and 45.8%, respectively, in the RR group; 86.6%, 51.7%, and 42.4%, respectively, in the LAT group; and 77.2%, 46.5%, and 38.4%, respectively, in the TACE group. On multivariate analysis, three independent factors related to survival after recurrences were identified. A single tumor nodule and AFP 
ISSN:0972-2068
0973-9793
DOI:10.1007/s12262-022-03343-1